Luego de que la firma Moderna, anunciara su eficacia del 94,5 %, esta mañana la compañía Pfizer sorprendió al confirmar la eficacia del 95 %, de su vacuna para prevenir el Covid-19. Cabe, destacar, que en su último anuncio, de la semana pasada, los resultados llegaban al 90%. BREAKING: We are proud to announce, along with @BioNTech_Group, that the Phase 3 study of our #COVID19 vaccine candidate has met all primary efficacy endpoints. — Pfizer Inc. (@pfizer) November 18, 2020The study reached 170 confirmed cases of #COVID19, with the #vaccine candidate BNT162b2 demonstrating 95% efficacy beginning 28 days after the first dose. — Pfizer Inc. (@pfizer) November 18, 2020We also plan to submit the efficacy and safety data from the study for peer-review in a scientific journal once analysis of the data is completed. — Pfizer Inc. (@pfizer) November 18, 2020 |